Insider Selling: Natera, Inc. (NASDAQ:NTRA) Insider Sells 1,196 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 1,196 shares of the firm’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total value of $141,379.16. Following the sale, the insider now directly owns 110,695 shares in the company, valued at approximately $13,085,255.95. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Tuesday, October 22nd, Solomon Moshkevich sold 256 shares of Natera stock. The stock was sold at an average price of $120.07, for a total value of $30,737.92.

Natera Stock Performance

NASDAQ NTRA opened at $124.16 on Friday. The company has a market cap of $15.36 billion, a PE ratio of -50.68 and a beta of 1.53. The stock’s 50 day simple moving average is $123.37 and its 200-day simple moving average is $111.99. Natera, Inc. has a 1-year low of $40.17 and a 1-year high of $133.54. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.97) earnings per share. As a group, equities research analysts anticipate that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Hedge Funds Weigh In On Natera

A number of institutional investors have recently added to or reduced their stakes in the stock. Covestor Ltd lifted its position in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares in the last quarter. Quent Capital LLC lifted its position in Natera by 3.2% during the first quarter. Quent Capital LLC now owns 3,205 shares of the medical research company’s stock worth $293,000 after buying an additional 99 shares in the last quarter. GAMMA Investing LLC lifted its position in Natera by 32.7% during the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its position in Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after buying an additional 135 shares in the last quarter. Finally, Private Advisor Group LLC lifted its position in Natera by 5.2% during the third quarter. Private Advisor Group LLC now owns 2,721 shares of the medical research company’s stock worth $346,000 after buying an additional 135 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently commented on NTRA shares. UBS Group dropped their target price on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Leerink Partners raised their target price on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th. Sanford C. Bernstein raised their price objective on Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday. Piper Sandler reissued an “overweight” rating and issued a $150.00 price objective on shares of Natera in a report on Friday, September 13th. Finally, Stephens reissued an “overweight” rating and issued a $125.00 price objective on shares of Natera in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $125.69.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.